Donald Rindell

Don Rindell has more than 30 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development, and device & diagnostic technology strategy for several US and European pharmaceutical and medical device companies.

Mr. Rindell is currently Managing Director of Camino International, LLC, a consulting practice for Business and Product Development. He is currently managing several partnered pharmacodiagnostic programs for Bristol Myers Squibb’s Translational Medicine initiatives in oncology. He previously served as Senior Director of Corporate Development at Amylin Pharmaceuticals, which was purchased by Bristol Myers Squibb. At Amylin, he led a number of key global transactions with companies including Shionogi Pharmaceuticals, Biocon, Takeda Pharmaceuticals and selected device delivery companies. He also provided management leadership to the Amylin Drug Delivery Team. He has previously held senior executive positions at CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, Hybritech, and Syntex.

Mr. Rindell received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.